Attendees at the American Thoracic Society (ATS) 2025 International Conference highlight global networking, scientific advancements, and professional development at this year's meeting.
At the American Thoracic Society (ATS) 2025 International Conference, attendees shared how the conference is a representation of knowledge exchange, collaboration, and advancing medical understanding in the pulmonary and critical care fields.
Here is what the following attendees who spoke with The American Journal of Managed Care® during the meeting had to say about why they attend the event:
This transcript was lightly edited; captions were auto-generated.
Transcript
What do you enjoy most about attending ATS?
Goulet: I think my favorite thing about being here is just being able to interact with our pulmonary and critical care colleagues from all over the world, and just seeing sort of what's new in our world of pulmonary medicine.
Ramakrishnan: Just catching up with everyone, colleagues around the world, learning what they're all up to, and even just catching up see how their family is going. [I've] worked with most of them, online and over correspondence; it's nice to see people in person.
Komori: I think it's just always really exciting to see all of the new science, both on the clinical front and also on the early preclinical data that's here from a lot of the people who are trying to develop medicines. And it's nice to see how people are engaging also with patients.
Mental Health Awareness: Transforming Workplace Support and Engagement
May 20th 2025Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
Listen
Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC
May 22nd 2025Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Mepolizumab Reduces COPD Exacerbations in Patients With Eosinophilic Inflammation
May 20th 2025New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of life in patients with eosinophilic chronic obstructive pulmonary disease (COPD).
Read More
FIBRONEER-ILD: Novel PDE4B Inhibitor Slows FVC Decline in Progressive Pulmonary Fibrosis
May 20th 2025Nerandomilast significantly slowed lung function decline and reduced mortality in patients with progressive pulmonary fibrosis (PPF), with consistent efficacy regardless of background antifibrotic therapy.
Read More